Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05865470

Age-dependent Effects of Smoked and Oral Delta-9-THC

This study will assess the age-dependent effects of smoked and oral THC on abuse liability, intoxication, analgesia and impairment as a function of age.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

About this study

The overall objective of this placebo-controlled, outpatient study is to compare the dose-dependent effects of smoked and oral THC on analgesia and endpoints directly related to adverse consequences of use including abuse liability, intoxication, and impairment as a function of age and sex.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or non-pregnant female aged 18-65 years according to the below criteria: EMERGING ADULTS: 18-25 years of age (+/- one year) MIDDLE-AGED ADULTS: 35-45 years of age (+/- one year) LATE MIDDLE-AGED ADULTS: 55-65 years of age (+/- one year)
  • Report weekly-monthly use of cannabis (with primary mode of use via inhalation) over the past 6 months prior to screening
  • Not currently seeking treatment for their cannabis use
  • No reported clinically significant adverse effects with cannabis use
  • Have a Body Mass Index from 18.5 - 34kg/m2
  • Able to perform all study procedures
  • FEMALES: Currently practicing an effective form of birth control if pre-menopausal

Exclusion criteria

  • Meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) criteria for any substance use disorder other than nicotine and mild cannabis use disorder
  • Report using other illicit drugs in the prior 4 weeks
  • Evidence of severe psychiatric illness (e.g. mood disorder with functional impairment or suicide risk, schizophrenia) or medical condition (i.e., hypertension) judged by the study physician (and PI to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
  • Current predominant licit use of medical cannabis
  • Current use of prescription or regular use of over the counter medications (with the exception of hormonal contraceptives and hormone replacement therapy). Current use of herbal supplements that may affect study outcomes or interact with study drug (i.e., St Johns wort, kava, L-tryptophan, melatonin)
  • If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures
  • Current pain
  • Pregnancy is exclusionary due to the possible effects of the study medication on fetal development
  • History of an allergic reaction or adverse reaction to cannabis is exclusionary.
  • Currently enrolled in another research protocol
  • Not using a contraceptive method (hormonal or barrier methods)
  • The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.
  • Intolerance to lactose and sesame (ingredients in the oral THC preparation)
  • Insensitivity to the Cold Pressor Test

Treatment and study plan

Cannabis

Drug

smoked cannabis

Other names: Smoked cannabis with THC

Dronabinol

Drug

Oral delta-9-THC

Other names: Delta-9-THC

Smoked Placebo

Drug

Placebo Cannabis

Other names: Placebo smoked cannabis (no THC)

oral placebo

Drug

Oral Placebo

Primary outcomes

  1. Subject-rated drug effects

    Time frame: 6 hours

    Average and peak subjective ratings of drug effects associated with abuse liability and intoxication as measured using visual analogue scales (VAS; 1-100mm).

  2. Analgesia as measured using the Cold Pressor Test

    Time frame: 6 hours

    Peak and average pain threshold and tolerance assessed using the Cold Pressor Test

  3. Impairment

    Time frame: 6 hours

    The primary outcome measure for performance will be the peak difference from baseline scores of the Global Impairment Score

  4. Pharmacokinetics of THC and metabolites

    Time frame: 6 hours

    Plasma levels of THC, 11-OH-THC, and THCCOOH

Study contacts

Contact information is provided by the study sponsor or research team.

Vincent Acebo

CONTACT

[email protected]

310-983-3417

Ziva D Cooper, PhD

CONTACT

[email protected]

310-983-3417

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Sex- and AGE-dependent Effects of Smoked and Oral Delta-9-THC

Acronym: SAGE

Important dates

Study start
2025
Primary completion
2028
Study completion
2029
First posted
May 18, 2023
Registry last updated
Jan 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.